TW201332581A - 口腔保健組成物(一) - Google Patents
口腔保健組成物(一) Download PDFInfo
- Publication number
- TW201332581A TW201332581A TW101148570A TW101148570A TW201332581A TW 201332581 A TW201332581 A TW 201332581A TW 101148570 A TW101148570 A TW 101148570A TW 101148570 A TW101148570 A TW 101148570A TW 201332581 A TW201332581 A TW 201332581A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- compound
- chloride
- weight
- quaternary ammonium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
本發明係關於水性口腔組成物,其包含陽離子類固醇化合物及四級銨鹽化合物;及其製造及使用之方法。
Description
本發明係關於水性口腔組成物,其包含陽離子類固醇化合物及四級銨鹽化合物;及其製造及使用之方法。
西拉真寧(Ceragenins)為陽離子類固醇抗微生物劑,其係由固醇骨幹合成而產生。
已知四級銨鹽化合物具有抗細菌活性且其等使用於口腔保健中亦為已知。然而,口腔保健產物含有四級銨鹽化合物與陽離子類固醇化合物一起之組合物者迄今仍未知。
本發明之某些具體例係提供水性口腔保健組成物,其包含:陽離子類固醇化合物;及四級銨鹽化合物。
其他具體例係提供治療口腔之疾病或症狀的方法,其包括將根據申請專利範圍中任一項之組成物給藥至需要其之個體的口腔。
本發明之適用性的其他領域可由下文中所提供之詳細說明而變得顯而易見。應瞭解當指明本發明之較佳具體例時,該詳細
說明及特定實例意欲僅用於闡明之目的且並非意欲限制本發明之範圍。
本發明之某些具體例係提供水性口腔保健組成物,其包含:陽離子類固醇化合物;及四級銨鹽化合物。
本文中所用之「水性」一詞係指以重量計至少約40%之自由水份。
於某些具體例中,該組成物包含以重量計自約40至約97%之自由水分。於某些具體例中,該組成物包含以重量計大於約50%之自由水分。於某些具體例中,該組成物包含以重量計自約50至約90%之自由水分。於某些具體例中,該組成物包含以重量計自約60至約85%之自由水分。於某些具體例中,該組成物包含以重量計自約73%至約83%之自由水分。某些具體例包含以重量計約74%、約75%、約76%、約77%、約78%、約79%、約80%、約81%或約82%之自由水分。
於某些具體例中,該陽離子類固醇化合物為式(I)化合物:
其中R1係選自於-OH及NH-R2,其中R2為C2-C14烷基、C2-C14烯基或C2-C14炔基(akynyl),且n為3或4。
某些具體例係提供組成物,其中該式(I)化合物係選自於式(II)化合物:
式(III)化合物:
於某些具體例中,該陽離子類固醇化合物為式(II)化合物:
於某些具體例中,該陽離子類固醇化合物具有分子量自約500至約1000。於某些具體例中,該陽離子類固醇化合物具有分子量自約650至約850。
於某些具體例中,該陽離子類固醇化合物係以該組成物之自約0.01%至約0.1重量%之濃度存在。於某些具體例中,該陽離子類固醇化合物係以該組成物之約0.05重量%之濃度存在。
於某些具體例中,該四級銨鹽化合物係選自於:苯烷銨氯化物(benzalkonium chloride)、苯索銨氯化物(benzethonium chloride)、甲基苯索銨氯化物、十六烷銨氯化物(cetalkonium chloride)、十六基吡錠氯化物、西曲銨(cetrimonium)、西曲溴銨(cetrimide)、多凡寧氯化物(dofanium chloride)、四乙基銨溴化物、十二基二甲基銨氯化物及度米氛溴化物(domiphen bromide)。於某些具體例中,該四級銨鹽化合物包含十六基吡錠氯化物。
四級銨鹽化合物為銨鹽之群組,其中有機基團已被原有銨陽離子之全部四個氫所取代。彼等具有中心氮原子,其係與四個有機基團及一個酸根連結。適用於本發明中之四級銨鹽化合物的實例進一步包括其他苯烷銨(benzalkonium)或苯索銨(benzethonium)鹵化物,包括,但不侷限於,苯烷銨或苯索銨溴化物或氟化物、十六基對烷基醯胺基丙烷銨氯化物(cetyl p-alkylamidopropalkonium chloride)、廿二碳烷銨氯化物(behenalkonium chloride)、山萮基三甲銨甲硫酸鹽(behentrimonium methosulphate)、山萮基醯胺基丙基乙基二銨乙硫酸鹽(behenamidopropylethyldimonium ethosulphate)、硬脂烷銨氯化物(stearalkonium chloride)、油烷銨氯化物(olealkonium chloride)、西曲銨氯化物(cetrimonium chloride)、地奎銨氯化物(dequalinium chloride)、N-肉豆蔻基-N-甲基-嗎福啉鎓(morpholinium)甲基硫酸酯、聚[N-[3-(二甲基銨基)丙基]-N'-[3-(伸乙基氧基伸乙基二甲基銨基)丙基]脲二氯化物]、α-4-[1-三(2-羥基乙基)銨氯化物-2-丁烯基]-ω-三(2-羥基乙基)銨氯化物、聚[氧基伸乙基(二甲基亞胺基)伸乙基(二甲基亞胺基)-伸乙基二氯化物]。
於某些具體例中,該四級銨鹽化合物係以該組成物之自約0.01%至約0.1重量%之濃度存在。於某些具體例中,該四級銨鹽化合物係以該組成物之約0.05重量%之濃度存在。
於某些具體例中,該陽離子類固醇化合物及該四級銨鹽化合物係以1:1按重量之比例,根據彼等各自之濃度存在於該組成物中。
本發明之某些具體例進一步包含氟化物離子來源,其中該氟化物離子來源係選自於氟化亞錫、氟化鈉、氟化鉀、磷酸單氟鈉、矽酸氟鈉、矽酸氟銨、氟化胺、氟化銨,及其二種或多種之組合物。於某些具體例中,該氟化物離子來源包含氟化鈉。
其他具體例係提供治療口腔之疾病或症狀之方法,其包括將根據申請專利範圍中任一項之組成物給藥至需要其之個體的口腔。於某些具體例中,該口腔之疾病或症狀為發炎性疾病或症狀。
於某些具體例中,該疾病或症狀係選自於牙齦炎、牙周炎,及齲齒。
於某些具體例中,本發明係提供治療口腔之發炎症狀之方法,其包括將包含陽離子類固醇化合物之組成物給藥至需要其之個體的口腔。
某些具體例係提供治療口臭之方法,其包括將有效數量之本發明的組成物給藥至需要其之個體的口腔。於某些具體例中,本發明之組成物降低由產臭味唾液細菌所生成之揮發性硫化合物(VSC)。
本案發明者業已發現陽離子類固醇化合物(例如,西拉真寧)與四級銨鹽化合物(例如,十六基吡錠氯化物)之組合物意外地提供增強之抗微生物活性。
本文中所用之「西拉吉寧(ceraginin)」係包括西拉吉寧之組合物且「四級銨鹽化合物」係包括四級銨鹽化合物之組合物。
西拉真寧為陽離子性類固醇抗生素(CSAs)。彼等可經合成製造且為小分子化學化合物,其係由具有胺基酸之固醇骨幹與附著於彼等之其他化學群組所組成。此等化合物具有淨正電荷,其係被靜電吸引至特定病毒、真菌及細菌之負電荷細胞膜。CSAs對此
等膜具有高的結合親和力且能夠快速地破壞該目標膜導致細胞快速死亡。
西拉吉寧(ceraginins)之陽離子特性係模仿胜肽之陽離子電荷。預期列入本發明中使用之西拉吉寧係於美國專利案號6,767,904中揭示。於一個具體例中,該西拉吉寧為式(II)化合物:
該西拉真寧及四級銨鹽化合物之生物活性可藉已知於此方面技藝之人士的標準方法,如「最低抑制濃度(MIC)」分析來測定,將於給定期間沒有觀察到光密度(OD)變化之最低濃度記錄為MIC。當單獨試驗該化合物對抗不含該化合物之控制組時,係確定化合物單獨之抗微生物效應。
或者,「分級抑制濃度(FIC)」亦可用於測定該化合物間之協乘作用。本發明中所用之「協乘性」及「協乘作用」一詞係指由施用二種或多種化合物以產生抗細菌效應大於由施用個別化合物所產生之抗細菌效應的總和,所引起之抗細菌效應。該FIC方法允許測定該化合物之組合物的協乘效應。FICs可例如藉由將一種化合物之棋盤式滴定於一個尺寸之微量滴定板上進行,且另一個化合物於另一個尺寸上進行。該FIC係藉著檢查一種化合物於另一種化合物之MIC上的影響而計算且反之亦然。一個FIC指出該化合物之影響係加成的且小於一之FIC指出協乘作用。於某些具體例中,小於0.7之FIC指出該化合物之間的協乘作用正在評估中。
如本文中所使用者,FIC可測定如下:FIC=A+B其中
A=(X+Y之組合物的MIC/(X單獨之MIC)
B=(X+Y之組合物的MIC/(Y單獨之MIC)。
本發明之抗微生物化合物之組合物係有效地對抗多種微生物如口腔細菌。此等細菌之實例包括,但無需限制於,黏放線菌(Actinomyces viscosus)、變異鏈球菌(Streptococcus mutans)、牙齦卟啉單胞菌(Porphyromonas gingivalis)、具核梭桿菌(Fusobacterium nucleatum)等。
於某些具體例中,本發明之組成物能夠於約30秒鐘後提供抗微生物之效應。該能力特別有利於本發明之具體例之潄口水形式,如30秒對應於潄口水通常使用之期間。
於某些具體例中,該組成物包含緩衝劑,例如,磷酸鈉緩衝劑(例如,單鹼式磷酸鈉及磷酸二鈉)。
於某些具體例中,該組成物包含濕潤劑。有用於本文中之濕潤劑包括多元醇如丙三醇、山梨糖醇、木糖醇或低分子量PEGs、亞烴二醇(alkylene glycol)如聚乙二醇或丙二醇。於各種具體例中,濕潤劑係操作用於防止該糊膏或凝膠組成物曝露於空氣中時變。於各種具體例中,濕潤劑亦可作用為甜味劑。
於某些具體例中,該濕潤劑係以約1至約40%各自按重量之數量存在。於某些具體例中,該濕潤劑為山梨糖醇。於某些具體例中,山梨糖醇係以自約5至約25重量%之濃度存在。於某些具體例中,山梨糖醇係以自約5至約15重量%之濃度存在。於某些具體例中,該山梨糖醇係以約10重量%之濃度存在。關於山梨糖醇於本文中係指通常市售可得於70%水溶液中之材料。於某些具體例中,該總濕潤劑濃度為自約1至約60%,以重量計。於某些具體例中,該濕潤劑為甘油。於某些具體例中,甘油係以自約5至約15重量%計之濃度存在。於某些具體例中,甘由係以約7.5重量%之濃度存在。於某些具體例中,該濕潤劑為丙二醇。於某些具體
例中,丙二醇係以約5至約15重量%之濃度存在。於某些具體例中,丙二醇係以約7重量%之濃度存在。
於某些具體例中,該組成物包含纖維質聚合物如羥基烷基甲基纖維素(如羥基丙基甲基纖維素、羥基丁基甲基纖維素、羥基乙基甲基纖維素、羥基甲基甲基纖維素及羥基乙基丙基甲基纖維素);羧基烷基甲基纖維素類(如羧基丙基甲基纖維素、羧基丁基甲基纖維素、羧基乙基甲基纖維素、羧基甲基甲基纖維素及羧基乙基丙基甲基纖維素);羥基烷基纖維素類(如羥基丙基纖維素、羥基丁基纖維素、羥基乙基纖維素、羥基甲基纖維素及羥基乙基丙基纖維素);烷基纖維素(如丙基纖維素、丁基纖維素、乙基纖維素、甲基纖維素);羧基烷基纖維素(如羧基丙基纖維素、羧基丁基纖維素、羧基乙基纖維素、羧基甲基纖維素及羧基乙基丙基纖維素),及其組合物。於某些具體例中,該纖維質聚合物包含羧基甲基纖維素。
於某些具體例中,該組成物包含樹膠聚合物如角叉菜膠、黃原膠,及其組合物。於某些具體例中,該樹膠聚合物包含黃原膠。
某些具體例包含聚丙烯酸酯聚合物或共聚物如碳聚物(carbomer)。於某些具體例中,該聚丙烯酸酯聚合物或共聚物係選自於丙烯酸與聚烯基聚醚交聯之均-及共聚物。丙烯酸之合成高分子量聚合物已知為碳聚物,其可為丙烯酸與烯丙醚季戊四醇、蔗糖之烯丙醚或丙烯之烯丙醚交聯之均聚物。碳聚物具有「碳聚物均聚物A型」之USP分類。碳聚物具有吸附、保水及膨脹其等之原體積至許多倍的能力。碳聚物編碼(910、934、940、941、971、974及934P)為該聚合物之分子量及特定組份之指徴。碳聚物係以商品名稱卡波姆(Carbopol)®市售可得自於盧比索(Lubrizol)公司及其他公司。
某些具體例提供組成物,其係藉合併如前面所述之任何本文中所說明之具體例的組成份而得到或可得到者。
於某些具體例中,該組成物係以選自於潄口水,潄口劑、慕斯(mousse)、泡沫、口噴霧劑、含片、鈉劑、牙科工具,及竉物保健產物之形式。於某些具體例中,該組成物為潄口水或潄口劑。
本發明之某些具體例係提供水性組成物,其包含下列以重量計之組成份:
某些具體例係提供治療口臭之方法,其包括將本發明之任何具體例給藥至需要其之個體的口腔。
某些具體例係包含著色劑。著色劑如染料可為食品色料添加物,其係目前於食品藥物&化妝品法令下證實可用於食品及吞嚥藥物中者,包括染料如FD&C紅色3號(四碘螢光素
(tetraiodofluorescein)之鈉鹽)、食品紅色17,6-羥基-5-{(2-甲氧基-5-甲基-4-磺苯基)偶氮基}-2-萘磺酸之二鈉鹽、食品黃色13,喹酞酮(quinophtalone)或2-(2-喹啉基)茚滿二酮之一及二磺酸之混合物的鈉鹽、FD&C黃色5號(4-對-磺苯基偶氮基-1-對-磺苯基-5-羥基吡唑-3-羧酸之鈉鹽)、FD&C黃色6號(對-磺苯基偶氮基-B-萘酚(naphtol)-6-單磺酸鹽之鈉鹽)、FD&C綠色3號(4-{[4-(N-乙基-對-磺基苄基胺基)-苯基]-(4-羥基-2-鋶苯基)-亞甲基}-[1-(N-乙基-N-對-磺基苄基)-DELTA-3,5-環己二烯亞胺(cyclohexadienimine)]之二鈉鹽、FD&C藍色1號(二苄基二乙基-二胺基-三苯基甲醇三磺酸酐之二鈉鹽)、FD&C藍色2號(靛藍之二磺酸之鈉鹽)及其多種比例之混合物。通常若包含著色劑,其係以極少量存在。
增香劑亦可包含於本發明之於某些具體例中。此等調味料可選自於合成香味油及增香芳族,及/或油、油脂樹脂及由植物、葉、花、果實等所導生之萃出物,及其組合物。代表性香味油包括:綠薄荷油、肉桂油、薄荷油、丁香油、月桂樹油、百里香油、雪松葉油、肉荳蔻仁油、鼠尾草油,及苦杏仁油。此等增香劑可個別地或於摻合物中使用。常用之香味包括薄荷味如薄荷、人工香草、肉桂衍生物,及各種水果香味,不管係個別地或於摻合物中使用。通常任何調味料或食品添加物,如那些說明於美國國家科學院出版專刊1274,63-258頁食品加工所使用之化學品中者可予以使用。典型地,若包含香味劑,其係按重量以0.01-1%存在。於某些具體例中,調味料可按重量以約0.2%存在。
甜味劑包括天然及人工甜味劑二者。適當之甜味劑包括水溶性甜化劑如單糖、雙糖,及多糖,如木糖、核糖、葡萄糖(右旋糖)、甘露糖、半乳糖、果糖(左旋糖)、蔗糖(白糖)、麥芽糖、水溶性人工甜味劑如可溶性糖精鹽,亦即,鈉或鈣糖精鹽,環己基磺醯胺酸鹽以二胜肽為底之甜味劑,如L-門冬胺酸所導生之甜味劑,如L-門冬胺醯-L-苯基丙氨酸甲基酯(阿斯巴甜(aspartame))。通
常,於特別之組成物時用來提供所想要之甜味程度而使用之甜味劑的有效數量係依所選擇之甜味劑變化。該數量通常為該組成物之約0.001%至約5%以重量計。於某些具體例中,該甜味劑為糖精鈉且係以該組成物按重量之約0.01%存在。
任意之口氣清新劑可予以提供。任何口腔上可接受之口氣清新劑可予以使用,包括無需限制鋅鹽如葡糖酸鋅、檸檬酸鋅及亞氯酸鋅、α-紫羅酮及其混合物。一種或多種口氣清新劑係任意以口氣清新有效之總數量存在。
該組成物可任意包括酒石控制(抗結石)劑。那些有用於本文中之酒石控制劑係包括磷酸鹽及多磷酸鹽(例如焦磷酸鹽)、聚胺基丙烷磺酸(AMPS)、聚烯烴磺酸酯、聚烯烴磷酸酯、二膦酸鹽如氮雜環烷-2,2-二膦酸鹽(例如,氮雜環庚烷-2,2-二膦酸)、N-甲基氮雜環戊烷-2,3-二膦酸、乙烷-1-羥基-1,1-二膦酸(EHDP)及乙烷-1-胺基-1,1-二膦酸鹽、膦酸基鏈烷羧酸及此等試劑之任何鹽,例如其等之鹼金屬及銨鹽。有用之無機磷酸鹽及多磷酸鹽包括單鹼式、二鹼式及三鹼式磷酸鈉、三多磷酸鈉、四多磷酸鹽、一-、二-、三-及四鈉焦磷酸鹽、三偏磷酸鈉、六偏磷酸鈉及其混合物,其中鈉可任意地被鉀或銨所替代。其他有用之抗結石劑包括聚羧基酯聚合物及聚乙烯基甲醚/順式丁烯二酸酐(PVME/MA)共聚物,如那些可得自於ISP公司(Wayne,N.J.)以甘特滋(Gantrez)TM商標名下者。
於某些具體例中,酒石控制劑係以自約0.01至10重量%之濃度存在。於某些具體例中,該酒石控制劑係以約1重量%之濃度存在。於某些具體例中,該酒石控制劑亦作用如緩衝劑。例如,於磷酸鹽緩衝系統中,單鹼式磷酸鈉係以自約0.01至約5重量%之濃度存在且磷酸二鈉係以自約0.01至約5重量%之濃度存在,該精確之比率係依於該配製物中之其他賦形劑及想要之pH而定。
抗氧化劑為另一類任意之添加物。任何口腔上可接受之抗氧化劑可予以使用,包括丁基化羥基苯甲醚(BHA)、丁基化羥基甲
苯(BHT)、維生素A、類胡蘿蔔素、維生素E、類黃鹼素(flavonoids)、多酚、抗壞血酸、草藥抗氧化劑、葉綠素、褪黑激素,及其混合物。
亦任意者,有用於例如改善口乾之唾液刺激劑可予以包括。任何口腔上可接受之唾液刺激劑可予以使用,包括但不侷限於食物酸如檸檬酸、乳酸、蘋果酸、琥珀酸、抗壞血酸、己二酸、反式丁烯二酸,及酒石酸,及其混合物。一種或多種唾液刺激劑係任意地以唾液刺激有效之總數量存在。
抗噬菌斑(例如,噬菌斑阻斷)劑可任意予以包括。任何口腔上可接受之抗噬菌斑可予以使用,包括但不侷限於亞錫、銅、鎂及鍶鹽,二甲聚矽氧烷(dimethicone)共聚醇如十六基二甲聚矽氧烷共聚醇、木瓜蛋白酶、葡糖澱粉酶、葡萄糖氧化酶、脲、乳酸鈣、甘油磷酸鈣、聚丙烯酸鍶及其混合物。
任意之去敏感劑包括檸檬酸鉀、氯化鉀、酒石酸鉀、碳酸氫鉀、草酸鉀、硝酸鉀、鍶鹽,及其混合物。
於某些具體例中,該方法包含使用如本文中所說明之組成物潄洗口腔之步驟。於某些具體例中,將5毫升或更多之該組成物潄口。於某些具體例中,使用10毫升或更多。於某些具體例中,使用10-50毫升。於某些具體例中,使用15-25毫升或更多。於某些具體例中,使用15毫升或更多。於某些具體例中,個人每日使用該組成物潄口多次。於某些具體例中,個人使用該組成物潄口多日。於某些具體例中,個人每4至6小時多至每日6次使用該組成物潄口。
如全文中所使用者,範圍係以簡略方式使用來說明該範圍內之各個及每一個數值。於該範圍內之任何數值可選擇作為該範圍之終點。此外,本文中所引證之所有的參考,其等之全部內容合併於本文中參考。萬一於本發明揭示內容中之定義與所引證之參考者發生衝突,則對照(controls)本發明之揭示內容。
除非另有指明,應瞭解於本文中及於本說明書中任何地方所表達之所有的百分比及數量係指重量百分比。所給定之數量係以該物質之活性重量計。
表1(於下)係說明用於本發明之二種範例組成物(組成物I及組成物II)之配製物。
本發明之某些具體例可根據下列之方法製備。預混合物係藉由添加丙二醇至容器中且添加甲醇到那裡而製備。將該組合物混合直到該甲醇分散。添加香味且混合約3分鐘。然後將水加至
主混合器且將該混合器開動。然後添加普朗尼(pluronics)直到其充分分散。然後將糖精、山梨酸鉀及式(II)化合物加至主混合器且予以混合約3分鐘。將檸檬酸加至主混合器且予以混合約5分鐘。將甘油加至該主混合器。將山梨糖醇加至該主混合器且予以混合約5分鐘。然後將該預混合物加至主混合器且予以混合約15分鐘。
為了評估最低抑制濃度(MICs),將於對數生長期中之24小時培育物的濃度藉稀釋於胰蛋白酶大豆肉汁(TSB)而調整,以便於610毫微米得到0.2之光密度。然後將該細菌培養物準備用於試驗。
製備三種溶液:(1)1% CPC溶液於乙醇中;(2)1%式(II)化合物溶液於水中;及(3)0.5%式(II)化合物+0.5% CPC。將該溶液以1:9稀釋於TSB中。將其等加至96-孔洞板且製成連續稀釋(2-倍)遍及該板。將該細菌接種體以0.2 OD,100微升加至每一個孔洞。將該板培育過夜且於翌日於板讀數器上讀數。
0.5% CSA-13+0.5% CPC is<0.4=協乘性
將水用作為負控制組。將0.04毫升之各個樣品加至GC頂層空間樣品瓶(headspace vial)中,將各樣品進行二重複試驗。唾液接種體係使用午餐後所收集之整個唾液的65%,30%去離子水,及
5% FTG介質而製備。將3毫升該唾液混合物加至含有該樣品之瓶中。將含有唾液混合物及樣品之瓶加蓋。
將加蓋的瓶於37℃水浴中振盪培育過夜。利用氣相色層分離法(GC)測定揮發性硫化合物(VSC)與負控制組相較所降低之數量。
於表3(於下)中所說明之數據顯示本發明之組成物有效降低揮發性硫化合物,且因此可能於治療口臭上有效。
於該分析中,使用二種螢光染料以獲得細菌生存能力之快速測量。
將來自混合物種細菌化學恆定培養之樣品,OD~0.6轉移至無菌1.5毫升微離心管中且於12,000 xg離心達10分鐘至製成細菌小丸。然後將該細菌再懸浮於100微升無菌磷酸鹽緩衝之食鹽水中(PBS)。將樣品用100微升(高劑量)或20微升(低劑量)潄口水或控制溶液處理。殺死係於30秒鐘後停止,如藉由添加1.35毫升D/E中和緩衝液(英維特金公司)所示者。將樣品於12,000 xg離心達10分鐘至製成細菌小丸且將小丸再懸浮於500微升無菌PBS中清洗,然後再次離心。將最終之樣品懸浮於150微升無菌PBS中且將等份量50微升轉移至無菌96-孔洞板之三個孔洞之每一個中,使用英維特金公司之BacLight活/死細菌存活性組具進行細菌染色。將含有二種染料(SYTO9染料[綠色]及錪源碘化物(propidium iodide)[紅色])之50微升2x溶液加至96-孔洞板之樣品中。將板於室溫培育15分鐘,避開光且於激動波長485毫微米及發射波長535
及635毫微米時進行螢光讀數。結果係以相對於經PBS處理之控制樣品之存活細胞百分比呈現。
表4(於下)說明數據顯示本發明之組成物於使用30秒後提供協乘抗微生物效應。
式(II)化合物之抗發炎活性係研究對抗分開實驗組中之6種人類發炎細胞素,PGE2、IL-1ß、IL-6、IL-8、TNF-α,及GM-CSF;首先對抗PGE2,然後對抗五種其他細胞素。將人類單核血球U937細胞與巨嗜細胞區分且然後使用熱殺死之牙齦卟啉單胞菌(P.gingivalis)(HKPG,1 x 108細胞)刺激該細胞而誘發細胞素產生。不同之發炎細胞素類型係由U973細胞所生成且釋放於上澄液中。
式(II)化合物具有較高之抗發炎功效對抗三種細胞素,IL-1 β、IL-6,及TNF-α。特定於濃度0.1 ppm時,式(II)化合物降低21%之IL-1 β、60%之IL-6及80%之TNF-α。
Claims (17)
- 一種水性口腔保健組成物,其包含:陽離子類固醇化合物;及四級銨鹽化合物。
- 如請求項第1項所請求之組成物,其中該組成物為潄口水。
- 如請求項第1或2項所請求之組成物,其中該陽離子類固醇化合物為式(I)化合物:
- 如請求項第3項所請求之組成物,其中該式(I)化合物係選自於式(II)化合物:
- 如前述請求項中任一項之組成物,其中陽離子類固醇化合物為式(II)化合物:
- 如前述請求項中任一項之組成物,其中該四級銨鹽化合物係選自於:苯烷銨氯化物(benzalkonium chloride)、苯索銨氯化物(benzethonium chloride)、甲基苯索銨氯化物、十六烷銨氯化物(cetalkonium chloride)、十六基吡錠氯化物、西曲銨(cetrimonium)、西曲胺(cetrimide)、多凡寧氯化物(dofanium chloride)、四乙基銨溴化物、十二基二甲基銨氯化物及度米氛溴化物(domiphen bromide)。
- 如前述請求項中任一項之組成物,其中該四級銨鹽化合物包含十六基吡錠氯化物。
- 如前述請求項中任一項之組成物,其中該陽離子類固醇化合物係以該組成物之自約0.01%至約0.1重量%之濃度存在。
- 如前述請求項中任一項之組成物,其中該四級銨鹽化合物係以該組成物之自約0.01%至約0.1重量%之濃度存在。
- 如前述請求項中任一項之組成物,其中該陽離子類固醇化合物及該四級銨鹽化合物係根據彼等各自之濃度,按重量以1:1之比例存在於該組成物中。
- 如前述請求項中任一項之組成物,其中該陽離子類固醇化合物係以該組成物之約0.05重量%之濃度存在。
- 如前述請求項中任一項之組成物,其中該四級銨鹽化合物係以該組成物之約0.05重量%之濃度存在。
- 如前述請求項中任一項之組成物,其進一步包含氟化物離子來源;其中該氟化物離子來源係選自於氟化亞錫、氟化鈉、氟化鉀、磷酸單氟鈉、矽酸氟鈉、矽酸氟銨、氟化胺、氟化銨,及其二種或多種之組合物。
- 如請求項第13項所請求之組成物,其中該氟化物離子來源包含氟化鈉。
- 一種治療口腔之疾病或症狀之方法,其包括如前述請求項中任一項之組成物投予至需要其之個體的口腔。
- 一種治療口腔之發炎症狀之方法,其包括將包含陽離子類固醇化合物之組成物給藥至需要其之個體的口腔。
- 一種降低揮發性硫化合物之方法,其包括將包含陽離子類固醇化合物之組成物投予至需要其之個體的口腔。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2011/066482 WO2013109236A2 (en) | 2011-12-21 | 2011-12-21 | Oral care compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201332581A true TW201332581A (zh) | 2013-08-16 |
TWI559936B TWI559936B (en) | 2016-12-01 |
Family
ID=48326382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW101148570A TWI559936B (en) | 2011-12-21 | 2012-12-20 | Oral care compositions |
Country Status (16)
Country | Link |
---|---|
US (2) | US9345655B2 (zh) |
EP (2) | EP3449900A1 (zh) |
JP (1) | JP6051230B2 (zh) |
KR (1) | KR20140116111A (zh) |
CN (1) | CN104379120A (zh) |
AR (1) | AR089372A1 (zh) |
AU (1) | AU2011385377B2 (zh) |
BR (1) | BR112014015144B1 (zh) |
CA (1) | CA2859325A1 (zh) |
IL (1) | IL233216A0 (zh) |
MX (1) | MX2014007496A (zh) |
NZ (1) | NZ626144A (zh) |
RU (1) | RU2625838C2 (zh) |
TW (1) | TWI559936B (zh) |
UA (1) | UA113298C2 (zh) |
WO (1) | WO2013109236A2 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2303026B1 (en) | 2008-06-17 | 2020-09-09 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
US8975310B2 (en) | 2011-07-20 | 2015-03-10 | Brigham Young University | Hydrophobic ceragenin compounds and devices incorporating same |
US8932614B2 (en) | 2011-08-25 | 2015-01-13 | Paul B. Savage | Incorporation of particulate ceragenins in polymers |
CA2852989C (en) | 2011-09-13 | 2021-06-29 | Brigham Young University | Compositions for treating bone diseases and broken bones |
US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
MX369385B (es) | 2011-09-13 | 2019-11-07 | Univ Brigham Young | Productos para cicatrizar heridas tisulares. |
US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
JP6051230B2 (ja) | 2011-12-21 | 2016-12-27 | ブリガム ヤング ユニバーシティ | 口腔ケア組成物 |
US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
EP3225113B1 (en) | 2012-05-02 | 2020-09-02 | Brigham Young University | Methods for making ceragenin particulate materials |
WO2014062960A1 (en) | 2012-10-17 | 2014-04-24 | Brigham Young University | Treatment and prevention of mastitis |
CA2897150C (en) | 2013-01-07 | 2021-07-13 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
RU2669800C2 (ru) * | 2013-03-15 | 2018-10-16 | Брихэм Янг Юниверсити | Способы лечения воспаления, аутоиммунных расстройств и боли |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
US9527883B2 (en) | 2015-04-22 | 2016-12-27 | Brigham Young University | Methods for the synthesis of ceragenins |
WO2016172543A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
KR20200041659A (ko) | 2018-10-12 | 2020-04-22 | 주식회사 엘지생활건강 | 구강 질환의 예방 또는 개선용 구강 위생 조성물 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1037074B (de) * | 1957-03-25 | 1958-08-21 | Schering Ag | Mundpflegemittel |
US3843779A (en) * | 1971-03-22 | 1974-10-22 | Colgate Palmolive Co | Process for preparing stable dentifrice |
US4289755A (en) * | 1980-11-03 | 1981-09-15 | Richardson-Vicks Inc. | Stable mouthwash compositions containing zinc and fluoride compounds |
US4661341A (en) | 1984-10-30 | 1987-04-28 | The Procter & Gamble Company | Oral compositions |
US5506354A (en) | 1985-09-12 | 1996-04-09 | The Upjohn Company | Imidazolylpiperazinyl steroids |
US4842593A (en) | 1987-10-09 | 1989-06-27 | The Procter & Gamble Company | Disposable absorbent articles for incontinent individuals |
US4865855A (en) | 1988-01-11 | 1989-09-12 | Kimberly-Clark Corporation | Antimicrobial absorbent food pad |
US4990338A (en) | 1988-05-09 | 1991-02-05 | Dow Corning Corporation | Antimicrobial superabsorbent compositions and methods |
US5356630A (en) | 1989-02-22 | 1994-10-18 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
US4972848A (en) | 1989-08-23 | 1990-11-27 | Medtronic, Inc. | Medical electrical lead with polymeric monolithic controlled release device and method of manufacture |
US5025754A (en) | 1990-02-01 | 1991-06-25 | David Plyler | Apparatus and method for providing drinking water to poultry |
GB9020075D0 (en) | 1990-09-14 | 1990-10-24 | Filler Aaron G | Contrast agents for magnetic resonance imaging of axonal transport |
US5310545A (en) * | 1991-04-11 | 1994-05-10 | Drore Eisen | Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter |
US5286479A (en) * | 1991-12-10 | 1994-02-15 | The Dow Chemical Company | Oral compositions for suppressing mouth odors |
JP2877636B2 (ja) | 1992-11-18 | 1999-03-31 | 積水化成品工業株式会社 | 抗菌性ドリップシート |
WO1995024415A1 (en) | 1994-03-10 | 1995-09-14 | Magainin Pharmaceuticals Inc. | Steroid derivatives, pharmaceutical compositions containing them, and their pharmaceutical uses |
SK283674B6 (sk) | 1993-03-12 | 2003-11-04 | Pharmacia & Upjohn Company | Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje |
US5407573A (en) | 1993-06-01 | 1995-04-18 | Alpine Water Purification, Inc. | Continuous flow water-purifying device |
JP3044367B2 (ja) | 1995-11-13 | 2000-05-22 | 三洋化成工業株式会社 | 抗菌性吸水剤組成物およびその製法 |
US6132765A (en) | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
US5897770A (en) | 1997-10-23 | 1999-04-27 | Plymouth Products, Inc. | Center core cartridge feeder insert |
ATE269086T1 (de) * | 1998-03-06 | 2004-07-15 | Univ Brigham Young | Antibiotische steroidderivate |
US6767904B2 (en) | 1998-03-06 | 2004-07-27 | Bringham Young University | Steroid derived antibiotics |
US6350738B1 (en) | 1998-03-06 | 2002-02-26 | Brigham Young University | Steroid derived antibiotics |
US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
NO990975A (no) * | 1999-03-01 | 2000-02-21 | Orix As | Oralt preparat som er effektivt mot halitose |
US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
US6551608B2 (en) | 2000-03-06 | 2003-04-22 | Porex Technologies Corporation | Porous plastic media with antiviral or antimicrobial properties and processes for making the same |
AU2001284934A1 (en) | 2000-08-15 | 2002-02-25 | Brigham Young University | Steroid derived antibiotics |
JP3435405B2 (ja) | 2000-11-24 | 2003-08-11 | 株式会社ティーセル研究所 | 家畜の乳房炎治療剤及びこれを用いた乳房炎の治療方法 |
US6514556B2 (en) | 2000-12-15 | 2003-02-04 | Ecolab Inc. | Method and composition for washing poultry during processing |
US6803066B2 (en) | 2001-01-18 | 2004-10-12 | Praxair Technology, Inc. | Sanitizing food products |
US20040170601A1 (en) | 2001-02-26 | 2004-09-02 | Strom Alan David Greve | Method of improving the growth performance of an animal |
JP4674980B2 (ja) * | 2001-02-26 | 2011-04-20 | サンスター株式会社 | アルコール無配合液体口腔用組成物 |
ES2189649B1 (es) | 2001-06-15 | 2004-09-16 | Oftrai S.L. | Nueva composicion desinfectante y antiseptica. |
US9056048B2 (en) | 2001-08-16 | 2015-06-16 | The Trustees Of The University Of Pennsylvania | Synthesis and use of cationic steroids for anti-inflammatory drug therapy |
AU2002324723B2 (en) | 2001-08-16 | 2007-10-25 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
DE10218147B4 (de) | 2002-04-23 | 2005-12-22 | Stockhausen Gmbh | Wasserabsorbierende, die Zersetzung von Körperflüssigkeiten verzögernde Polymerteilchen, deren Herstellung und Verwendung |
US6689342B1 (en) * | 2002-07-29 | 2004-02-10 | Warner-Lambert Company | Oral care compositions comprising tropolone compounds and essential oils and methods of using the same |
BR0314763A (pt) | 2002-09-23 | 2005-07-26 | Schering Corp | Tratamento de infecções fúngicas |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7659061B2 (en) | 2002-11-19 | 2010-02-09 | Pharmacia & Upjohn Company | Pharmaceutical compositions having a modified vehicle |
US7282214B2 (en) | 2002-12-19 | 2007-10-16 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with antimicrobial coatings |
DK1608407T3 (da) | 2003-03-20 | 2006-12-04 | Pharmacia Corp | Dispergébar formulering af et antiinflammatorisk middel |
AU2004248898B2 (en) | 2003-06-23 | 2010-03-18 | Beiersdorf Ag | Antimicrobial wounddressing |
DE10328261B4 (de) | 2003-06-23 | 2007-10-25 | Beiersdorf Ag | Desinfizierende Auflage mit Silberbeschichtung und ihre Verwendung |
GB0318901D0 (en) | 2003-08-12 | 2003-09-17 | Univ Bath | Improvements in or relating to bone substitute material |
US6872303B2 (en) | 2003-08-12 | 2005-03-29 | Ian M. Knapp | Water treatment cartridge |
US20050267051A1 (en) | 2003-12-19 | 2005-12-01 | Lee Henry J | Antineoplastic and anti-HIV conjugates of steroid acid and nucleosides |
US9241885B2 (en) * | 2004-01-29 | 2016-01-26 | The Procter & Gamble Company | Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20060062773A1 (en) | 2004-09-21 | 2006-03-23 | The Procter & Gamble Company | Compositions for maintaining and restoring normal gastrointestinal flora |
ES2355064T3 (es) | 2005-09-08 | 2011-03-22 | Kabushiki Kaisha Yakult Honsha | Inhibidor de la absorción de colesterol. |
WO2007089906A2 (en) * | 2006-02-01 | 2007-08-09 | Brigham Young University | Cationic steroid antimicrobial compositions for treating or preventing herpes infections |
US20070191322A1 (en) | 2006-02-01 | 2007-08-16 | Savage Paul B | Cationic Steroid Microbial Compositions and Methods of Use |
WO2008048340A2 (en) * | 2006-02-01 | 2008-04-24 | Brigham Young University | Cationic steroid antimicrobial compositions for treating poxvirus infections |
WO2007089907A2 (en) | 2006-02-01 | 2007-08-09 | Brigham Young University | Cationic steroid antimicrobial compositions and methods of use |
WO2007134176A2 (en) | 2006-05-10 | 2007-11-22 | Microban Products Company | Antimicrobial food pad |
US7858000B2 (en) | 2006-06-08 | 2010-12-28 | Novartis Ag | Method of making silicone hydrogel contact lenses |
US8685421B2 (en) | 2006-07-07 | 2014-04-01 | Surmodics, Inc. | Beaded wound spacer device |
WO2008038965A1 (en) | 2006-09-26 | 2008-04-03 | Kyungpook National University Industry-Academic Cooperation Foundation | 7alpha-aminosteroid derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for anticancer or antibiotics containing the same as an active ingredient |
US7854941B2 (en) | 2007-02-12 | 2010-12-21 | The University Of Southern Mississippi | Method of attaching drug compounds to non-reactive polymer surfaces |
US20090016973A1 (en) | 2007-07-09 | 2009-01-15 | Micropure, Inc. | Composition and Method for the Prevention of Oral Disease |
US8558051B2 (en) | 2007-07-18 | 2013-10-15 | The Procter & Gamble Company | Disposable absorbent article having odor control system |
US8772220B2 (en) | 2007-08-24 | 2014-07-08 | Sekisui Specialty Chemicals America, Llc | Chemical delivery product and process for making the same |
US20090068122A1 (en) | 2007-09-06 | 2009-03-12 | Shira Pilch | Dentifrice Compositions for Treating Xerostomia |
WO2009079066A2 (en) | 2007-09-26 | 2009-06-25 | Aparna Biosciences | Therapeutic and vaccine polyelectrolyte nanoparticle compositions |
GB0724278D0 (en) * | 2007-12-13 | 2008-01-30 | Syntopix Ltd | uses for antimicrobial agents |
EP2303026B1 (en) | 2008-06-17 | 2020-09-09 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
US20090324517A1 (en) | 2008-06-30 | 2009-12-31 | Dan Kline | Halitosis treatment |
AU2009268528B2 (en) | 2008-07-09 | 2015-11-05 | Board Of Regents Of The University Of Nebraska | Functional micelles for hard tissue targeted delivery of chemicals |
WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
US8557031B1 (en) | 2010-01-07 | 2013-10-15 | Sandia Corporation | Methods for attaching polymerizable ceragenins to water treatment membranes using amine and amide linkages |
US9180132B2 (en) * | 2010-03-04 | 2015-11-10 | The Trustees Of The University Of Pennsylvania | Antimicrobial cationic steroids and methods of use |
US8871716B2 (en) | 2010-10-08 | 2014-10-28 | Korea Advanced Institute Of Science And Technology | Use of antimicrobial peptides in regeneration of skin cells |
WO2012061651A1 (en) | 2010-11-03 | 2012-05-10 | Brigham Young University | Articles incorporating absorbert polymer and ceragenin compound |
GB201021937D0 (en) | 2010-12-24 | 2011-02-02 | Reckitt & Colman Overseas | Skin sanitizer compositions comprising alcohol based emulsion |
CN102172356B (zh) | 2011-03-03 | 2013-04-03 | 山东农业大学 | 牛磺鹅去氧胆酸在制备防治骨质疏松的药物中的应用 |
US8810380B2 (en) | 2011-07-01 | 2014-08-19 | Gerald F. Leitz | Golf scoring management system |
US8975310B2 (en) | 2011-07-20 | 2015-03-10 | Brigham Young University | Hydrophobic ceragenin compounds and devices incorporating same |
WO2013029059A1 (en) | 2011-08-25 | 2013-02-28 | Brigham Young University | Medical devices incorporating ceragenin-containing composites |
WO2013029055A1 (en) | 2011-08-25 | 2013-02-28 | Brigham Young University | Incorporation of particulate ceragenins in polymers |
US8932614B2 (en) | 2011-08-25 | 2015-01-13 | Paul B. Savage | Incorporation of particulate ceragenins in polymers |
MX369385B (es) | 2011-09-13 | 2019-11-07 | Univ Brigham Young | Productos para cicatrizar heridas tisulares. |
JP6051230B2 (ja) | 2011-12-21 | 2016-12-27 | ブリガム ヤング ユニバーシティ | 口腔ケア組成物 |
BR112014021505A2 (pt) | 2012-03-01 | 2017-07-18 | Univ Brigham Young | composições de processamento de alimentos antimicrobianas incluindo compostos de ceragenina e métodos de uso |
US20130280391A1 (en) | 2012-04-24 | 2013-10-24 | Brigham Young University | Anti-microbial wash compositions including ceragenin compounds and methods of use for treating non-meat food products |
WO2014062960A1 (en) | 2012-10-17 | 2014-04-24 | Brigham Young University | Treatment and prevention of mastitis |
CA2897150C (en) | 2013-01-07 | 2021-07-13 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
RU2669800C2 (ru) | 2013-03-15 | 2018-10-16 | Брихэм Янг Юниверсити | Способы лечения воспаления, аутоиммунных расстройств и боли |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
-
2011
- 2011-12-21 JP JP2014548757A patent/JP6051230B2/ja not_active Expired - Fee Related
- 2011-12-21 BR BR112014015144-0A patent/BR112014015144B1/pt not_active IP Right Cessation
- 2011-12-21 NZ NZ626144A patent/NZ626144A/en not_active IP Right Cessation
- 2011-12-21 EP EP18167462.3A patent/EP3449900A1/en not_active Withdrawn
- 2011-12-21 CN CN201180075880.3A patent/CN104379120A/zh active Pending
- 2011-12-21 KR KR1020147019874A patent/KR20140116111A/ko not_active Application Discontinuation
- 2011-12-21 AU AU2011385377A patent/AU2011385377B2/en not_active Ceased
- 2011-12-21 RU RU2014129813A patent/RU2625838C2/ru not_active IP Right Cessation
- 2011-12-21 CA CA2859325A patent/CA2859325A1/en not_active Abandoned
- 2011-12-21 MX MX2014007496A patent/MX2014007496A/es unknown
- 2011-12-21 WO PCT/US2011/066482 patent/WO2013109236A2/en active Application Filing
- 2011-12-21 UA UAA201408158A patent/UA113298C2/uk unknown
- 2011-12-21 US US14/364,283 patent/US9345655B2/en active Active
- 2011-12-21 EP EP11875594.1A patent/EP2793832B1/en not_active Not-in-force
-
2012
- 2012-12-20 AR ARP120104872A patent/AR089372A1/es unknown
- 2012-12-20 TW TW101148570A patent/TWI559936B/zh not_active IP Right Cessation
-
2014
- 2014-06-18 IL IL233216A patent/IL233216A0/en unknown
-
2015
- 2015-10-29 US US14/926,738 patent/US20160045421A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2793832B1 (en) | 2018-05-23 |
MX2014007496A (es) | 2015-02-17 |
BR112014015144A2 (pt) | 2017-06-13 |
US9345655B2 (en) | 2016-05-24 |
CA2859325A1 (en) | 2013-07-25 |
EP3449900A1 (en) | 2019-03-06 |
AU2011385377A1 (en) | 2014-07-03 |
US20140369941A1 (en) | 2014-12-18 |
AR089372A1 (es) | 2014-08-20 |
TWI559936B (en) | 2016-12-01 |
IL233216A0 (en) | 2014-08-31 |
JP6051230B2 (ja) | 2016-12-27 |
AU2011385377B2 (en) | 2017-06-01 |
EP2793832A2 (en) | 2014-10-29 |
NZ626144A (en) | 2016-05-27 |
KR20140116111A (ko) | 2014-10-01 |
RU2625838C2 (ru) | 2017-07-19 |
US20160045421A1 (en) | 2016-02-18 |
RU2014129813A (ru) | 2016-02-10 |
UA113298C2 (xx) | 2017-01-10 |
JP2015502978A (ja) | 2015-01-29 |
WO2013109236A3 (en) | 2013-10-10 |
WO2013109236A2 (en) | 2013-07-25 |
BR112014015144B1 (pt) | 2018-03-27 |
CN104379120A (zh) | 2015-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201332581A (zh) | 口腔保健組成物(一) | |
US20170035677A1 (en) | Oral care compositions | |
AU2014364436B2 (en) | Dentifrice compositions comprising zinc oxide and zinc citrate | |
CA2554730C (en) | Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials | |
RU2609862C2 (ru) | Водные композиции по уходу за полостью рта | |
US5560906A (en) | Non-alcoholic antimicrobial mouthwash for removal of dental plaque | |
JP7251998B2 (ja) | 液体口腔用組成物 | |
TWI492752B (zh) | 水性口腔護理組成物 | |
ZA200407503B (en) | Anti-microbial breath freshening mouthrinse | |
CN107320368B (zh) | 一种含艾灰的成人用牙膏及其制备方法 | |
RU2726198C2 (ru) | Композиции для ухода за полостью рта | |
RU2312657C2 (ru) | Ополаскиватель для полости рта | |
JP2017031201A (ja) | 口腔ケア組成物 | |
KR102597684B1 (ko) | 아마란스 추출물을 포함하는 구강용 조성물 | |
Schäfer et al. | In vivo evaluation of an oral health toothpaste with 0.1% vitamin E acetate and 0.5% sunflower oil (with vitamin F) | |
KR102597685B1 (ko) | 파슬리 추출물을 포함하는 구강용 조성물 | |
KR102379228B1 (ko) | 차이브 추출물을 포함하는 구강용 조성물 | |
WO2019002462A1 (en) | COMPOSITION COMPRISING AN ANTISEPTIC, A VOLATILE SOFT COMPOUND NEUTRALIZER AND AN ANTI-CATIONIC AGENT | |
BR112017012628B1 (pt) | composição de enxágue bucal para cuidado oral e uso de pelo menos uma fonte de estanho iônico e de polivinilpirrolidona | |
JP2001278799A (ja) | 抗う蝕剤 | |
BR0105471B1 (pt) | Formulações à base de própolis para uso odontológico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |